Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease
RAHWAY, N.J.--(BUSINESS WIRE)--Oct 17, 2023--
Source: eagletribune.com